On October 26, Gilead’s tenofovir (Viread) became the only new anti-HIV drug to win FDA OK this year. The drug got the green light for use by anyone with HIV, despite an un-precedented -- and, to the small biotech and activists alike, improper -- advisory-committee rec that it be used only by those with drug resistance or advanced AIDS. Why so heavy-handed, Uncle Sam? Tenofovir not only offers once-daily dosing, but also looks good for salvage therapy.